AstraZeneca’s new inhaler fails to match GSK’s drug in a clinical trial

By PharmaCompass

2018-08-30

Impressions: 197 Article

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) for chronic lung disease posted disappointing results last week as it proved worse than rival GlaxoSmithKline’s product Anoro Ellipta (umeclidinium/vilanterol) in a clinical trial.

AstraZeneca said the results were inconsistent with earlier findings as it waits for European authorities to approve the inhaler later this year.

The study found that Bevespi Aerosphere was as good as GSK’s product in improving peak breathing levels when patients exhaled, but it failed to match Anoro on trough measures.

Both drugs were already FDA-approved and are on the market for chronic obstructive pulmonary disease (COPD). GSK’s Anoro Ellipta was approved by the FDA in December 2013 and generated US$ 482 million in sales, while AstraZeneca’s Bevespi Aerosphere obtained an approval in April 2016 and had sales of only US$ 16 million.

COPD is a huge space within respiratory diseases, globally affecting about 384 million people.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass